Table 1.

Characteristics of the included studies

Study (reference no.)	Year	Study design (NCT No.)	Interventions	Sex (male/female),Age (mean ± SD)	Baseline Migraine-days per month (mean ± SD)	Follow-up
Uwe Reuter [14]	2018	RCT phase3b, NCT03096834	erenumab 140 mg Placebo	24/97,44.6 ± 10.5 22/103,44.2 ± 10.6	9.2 ± 2.6 9.3 ± 2.7	12w
David W Dodick [15]	2017	RCT phase 3, NCT02483585	erenumab 70 mg Placebo	41/245,42 ± 11 44/247,42 ± 12	8.1 ± 2.7 8.4 ± 2.6	12w
Peter J. Goadsby [24]	2017	RCT phase 3, NCT02456740	erenumab 70 mg Placebo	49/268,41.1 ± 11.3 45/274,41.3 ± 11.2	8.3 ± 2.5 8.2 ± 2.5	24w
Hong Sun [25]	2016	RCT phase 2, NCT01952574	erenumab 70 mg Placebo	25/82, 42.6 ± 9.9 28/132,41.4 ± 10.0	8.6 ± 2.5 8.8 ± 2.7	12w
David W Dodick [26]	2014	RCT phase 2, NCT01772524	Eptinezumab 1000 mg Placebo	14/67,38.6 ± 10.8 16/66,39.0 ± 9.6	8.4 ± 2.1 8.8 ± 2.7	12w
David W. Dodick [16]	2018	RCT phase 3, NCT02629861	Fremanezumab 225 mg Placebo	46/244,42.9 ± 12.7 47/247, 41.3 ± 12.0	8.9 ± 2.6 9.1 ± 2.7	12w
Marcelo E Bigal [27]	2015	RCT phase 2b, NCT02025556	Fremanezumab 225 mg Placebo	9/87,40.8 ± 12.4 12/92,42.0 ± 11.6	11.5 ± 1.9 11.5 ± 2.24	12w
Vladimir Skljarevski# [28]	2018	RCT phase 2b, NCT02163993	Galcanezumab 120 mg Placebo	42/231,40.6 ± 11.9 28/109,39.5 ± 12.1	6.7 ± 2.6 6.6 ± 2.7	12w
Vladimir Skljarevski [18]	2017	RCT Phase 3, NCT02614196	galcanezumab 120 mg Placebo	34/197,40.9 ± 11.2 68/393,42.3 ± 11.3	9.07 ± 2.9 9.2 ± 3.0	24w
Virginia L. Stauffer [17]	2018	RCT phase 3, NCT02614183	galcanezumab 120 mg Placebo	32/181,40.9 ± 11.9 71/362,41.3 ± 11.4	9.2 ± 3.1 9.1 ± 3.0	24w
David W Dodick [29]	2014	RCT phase 2, NCT01625988	galcanezumab 150 mg Placebo	19/88,40.9 ± 11.4 14/96,41.9 ± 11.7	6.7 ± 2.4 7.0 ± 2.5	12w

RCT Randomized controlled trial, SD Standard deviation. #The specific information can only be achieved in the total CGRP monoclonal antibodies treatment group